Lantheus Holdings Contact | Compliance | Reimbursement | Supply Updates | Supplier Link
Investor Relations

A HERITAGE OF INNOVATION AND LEADERSHIP

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (“Lantheus”), which is a global leader in developing, manufacturing, selling and distributing innovative diagnostic image agents and products.

Our expertise in discovering, developing and commercializing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough tools for the diagnosis and management of disease. Lantheus has a rich heritage and expertise in cardiovascular imaging and nuclear medicine, having pioneered many of the most significant products used in medical imaging.

Our current imaging agents primarily assist in the diagnosis of heart, vascular and other diseases using nuclear imaging, echocardiography and magnetic resonance imaging (MRI) technologies. We have a pipeline of next-generation and first-in-class products using Positron Emission Tomography (PET) and MRI technologies.

Our vision is to be the leading provider of innovative medical imaging solutions to improve human life. We are committed to developing next generation and first-in-class imaging agents to assist physicians in the diagnosis of heart, vascular and other diseases.

With direct operations in the United States, Puerto Rico, Canada and Australia, we have a long and distinguished history of developing and commercializing innovative market-changing products.

Recent News

LANTHEUS ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING AND DEBT REFINANCING

No. BILLERICA, Mass. (June 30, 2015) – Lantheus Holdings, Inc. (“Lantheus Holdings” or the “Company”), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents and products, announced today the closing of its initial public offering of 12,256,577 shares of its common stock (including 1,423,243 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares) at a public offering price of $6.00 per share (“the Offering”), resulting in estimated net proceeds of approximately $66.7 million, after deducting underwriting commissions and estimated expenses. The Company’s common stock is listed on The NASDAQ Global Market under the trading symbol “LNTH.”

click here for the press release

Company Spotlight

© 2015 Lantheus Medical Imaging, Inc. Contact | Compliance | Reimbursement | Supply Updates | Supplier Link | Site Map